Alta Capital Management Stake in Markel (MKL) Has Upped as Market Valuation Rose; As Merck & Co. (MRK) Market Valuation Rose, Holder Martin & Company Has Lowered Its Position by $1.89 Million

June 14, 2018 - By Peter Erickson

Merck & Co., Inc. (NYSE:MRK) Logo

Alta Capital Management Llc increased its stake in Markel Corp (MKL) by 3.24% based on its latest 2018Q1 regulatory filing with the SEC. Alta Capital Management Llc bought 600 shares as the company’s stock rose 0.57% while stock markets declined. The institutional investor held 19,094 shares of the property-casualty insurers company at the end of 2018Q1, valued at $22.34 million, up from 18,494 at the end of the previous reported quarter. Alta Capital Management Llc who had been investing in Markel Corp for a number of months, seems to be bullish on the $15.28 billion market cap company. The stock increased 0.01% or $0.15 during the last trading session, reaching $1099.9. About 34,847 shares traded or 15.96% up from the average. Markel Corporation (NYSE:MKL) has risen 14.67% since June 14, 2017 and is uptrending. It has outperformed by 2.10% the S&P500. Some Historical MKL News: 24/04/2018 – MARKEL CORP – BOOK VALUE PER COMMON SHARE OUTSTANDING OF $671.05 AT MARCH 31, 2018, DOWN 2% FROM $683.55 AT DECEMBER 31, 2017; 07/05/2018 – MARKEL, APOLLO, BLACKSTONE MAY HAVE MADE BIDS: REINSURANCE.COM; 24/04/2018 – Markel Swings to Loss After Accounting Change, Special Item; 15/05/2018 – Pink’s Hot Dogs Celebrates the Royal Wedding of Prince Harry and Meghan Markel; 10/05/2018 – Boost Insurance Secures Dedicated Reinsurance Capacity Built To Power lnsurtech Startups; 21/05/2018 – Markel Closes Above 50-Day Moving Average: Technicals; 10/05/2018 – Boost Insurance Secures Dedicated Reinsurance Capacity Built To Power Insurtech Startups

Martin & Company Inc decreased its stake in Merck & Co. Inc. (MRK) by 65.7% based on its latest 2018Q1 regulatory filing with the SEC. Martin & Company Inc sold 34,998 shares as the company’s stock rose 5.40% while stock markets declined. The institutional investor held 18,269 shares of the health care company at the end of 2018Q1, valued at $995,000, down from 53,267 at the end of the previous reported quarter. Martin & Company Inc who had been investing in Merck & Co. Inc. for a number of months, seems to be less bullish one the $165.62 billion market cap company. The stock decreased 0.89% or $0.55 during the last trading session, reaching $61.56. About 11.95M shares traded or 6.42% up from the average. Merck & Co., Inc. (NYSE:MRK) has declined 9.15% since June 14, 2017 and is downtrending. It has underperformed by 21.72% the S&P500. Some Historical MRK News: 07/05/2018 – MERCK FINCK CEO MATTHIAS SCHELLENBERG COMMENTS IN INTERVIEW; 27/03/2018 – ADVISORY-Alerts on Merck & Co’s fast-track designation for tepotinib withdrawn; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination; 06/04/2018 – Top 3 includes: #1 — added $BMY UPDATED: Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte $INCY $MRK; 27/03/2018 – U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC; 17/05/2018 – Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab); 25/05/2018 – Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone; 27/03/2018 – MERCK KGAA GETS FAST-TRACK DESIGNATION FOR TEPOTINIB IN JAPAN; 23/05/2018 – Merck’s Keytruda succeeds late-stage lung cancer study; 15/04/2018 – Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at

Martin & Company Inc, which manages about $1.98 billion and $300.36M US Long portfolio, upped its stake in Select Sector Spdr (XLI) by 35,067 shares to 107,997 shares, valued at $8.02M in 2018Q1, according to the filing. It also increased its holding in Consolidated Communications Ho (NASDAQ:CNSL) by 75,455 shares in the quarter, for a total of 158,672 shares, and has risen its stake in Collectors Universe Inc. (NASDAQ:CLCT).

Investors sentiment increased to 1 in 2018 Q1. Its up 0.06, from 0.94 in 2017Q4. It improved, as 72 investors sold MRK shares while 603 reduced holdings. 114 funds opened positions while 561 raised stakes. 1.91 billion shares or 1.08% less from 1.93 billion shares in 2017Q4 were reported. Moreover, Kdi Cap Prns Ltd Co has 2.3% invested in Merck & Co., Inc. (NYSE:MRK). Old National Bank In reported 89,216 shares or 0.26% of all its holdings. Grandfield Dodd Limited Liability Com, New York-based fund reported 339,012 shares. North Star Inv Mngmt Corp holds 0.32% in Merck & Co., Inc. (NYSE:MRK) or 48,755 shares. Associated Banc reported 251,157 shares. Gargoyle Investment Advisor Ltd Company reported 46,539 shares stake. Mark Sheptoff Fincl Planning Ltd Limited Liability Company invested in 0.02% or 400 shares. Nippon Life Insur, Japan-based fund reported 567,400 shares. Private Ocean Lc reported 0.05% in Merck & Co., Inc. (NYSE:MRK). Lipe And Dalton reported 2,487 shares. Pinnacle Limited holds 535,303 shares or 0.57% of its portfolio. Td Capital Mgmt Ltd Limited Liability Company invested in 2,057 shares or 0.03% of the stock. New England Research And reported 31,665 shares. Hollencrest Capital Mgmt stated it has 11,529 shares. Mitsubishi Ufj holds 270 shares or 0.06% of its portfolio.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Streetinsider.com which released: “Merck (MRK) Says FDA Granted Priority Review to its sBLA for GARDASIL9 in Women and Men Ages 27 to 45 for …” on June 13, 2018, also Businesswire.com with their article: “(pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)” published on June 13, 2018, 247Wallst.com published: “Merck Wins Another FDA Approval For Keytruda” on June 14, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma’s Q4 Miss, Sage Inks Deal With Japan’s …” published on June 14, 2018 as well as 247Wallst.com‘s news article titled: “General Electric, JPMorgan Weaken the Dow Thursday” with publication date: June 14, 2018.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on July, 27. They expect $1.04 earnings per share, up 2.97% or $0.03 from last year’s $1.01 per share. MRK’s profit will be $2.80 billion for 14.80 P/E if the $1.04 EPS becomes a reality. After $1.05 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -0.95% negative EPS growth.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Merck & Co. Inc. had 90 analyst reports since August 13, 2015 according to SRatingsIntel. Jefferies upgraded the stock to “Hold” rating in Tuesday, October 31 report. The firm has “Sell” rating given on Thursday, May 25 by Jefferies. The firm earned “Buy” rating on Wednesday, October 18 by Citigroup. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Overweight” rating by Barclays Capital on Thursday, April 5. The company was maintained on Friday, September 9 by Barclays Capital. The stock has “Hold” rating by SunTrust on Monday, October 30. As per Monday, September 21, the company rating was maintained by JP Morgan. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Sell” rating by BMO Capital Markets on Tuesday, July 4. SunTrust upgraded the stock to “Buy” rating in Tuesday, January 16 report. The company was maintained on Tuesday, June 14 by Jefferies.

Among 5 analysts covering Markel Corporation (NYSE:MKL), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Markel Corporation had 13 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating by SunTrust given on Wednesday, February 7. On Monday, August 28 the stock rating was maintained by RBC Capital Markets with “Hold”. The stock has “Hold” rating by SunTrust on Friday, October 27. The rating was downgraded by RBC Capital Markets on Friday, August 7 to “”. RBC Capital Markets maintained Markel Corporation (NYSE:MKL) rating on Wednesday, February 7. RBC Capital Markets has “Hold” rating and $1200.0 target. As per Wednesday, July 26, the company rating was maintained by Boenning & Scattergood. As per Thursday, August 4, the company rating was maintained by SunTrust. On Thursday, April 14 the stock rating was upgraded by William Blair to “Outperform”. William Blair upgraded Markel Corporation (NYSE:MKL) on Monday, March 19 to “Buy” rating. The firm has “Hold” rating by RBC Capital Markets given on Monday, October 2.

Alta Capital Management Llc, which manages about $1.48B and $1.61B US Long portfolio, decreased its stake in Visa (NYSE:V) by 6,758 shares to 268,301 shares, valued at $32.09M in 2018Q1, according to the filing. It also reduced its holding in Cognizant Tech Solutns (NASDAQ:CTSH) by 5,338 shares in the quarter, leaving it with 660,397 shares, and cut its stake in Union Pacific (NYSE:UNP).

Another recent and important Markel Corporation (NYSE:MKL) news was published by Nasdaq.com which published an article titled: “Report: Developing Opportunities within Abbott Laboratories, Markel, Microsoft, Gazit-Globe, National General, and …” on June 14, 2018.

Markel Corporation (NYSE:MKL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts